These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors. Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669 [TBL] [Abstract][Full Text] [Related]
26. Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs. Guo C; Dai X; Du Y; Xiong X; Gui X Cancer Immunol Immunother; 2024 Aug; 73(10):210. PubMed ID: 39123089 [TBL] [Abstract][Full Text] [Related]
27. Targeting activity of a TCR/IL-2 fusion protein against established tumors. Wen J; Zhu X; Liu B; You L; Kong L; Lee HI; Han KP; Wong JL; Rhode PR; Wong HC Cancer Immunol Immunother; 2008 Dec; 57(12):1781-94. PubMed ID: 18369620 [TBL] [Abstract][Full Text] [Related]
28. Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells. Jounaidi Y; Cotten JF; Miller KW; Forman SA Cancer Res; 2017 Nov; 77(21):5938-5951. PubMed ID: 28916655 [TBL] [Abstract][Full Text] [Related]
31. Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy. Hu Q; Ye X; Qu X; Cui D; Zhang L; Xu Z; Wan H; Zhang L; Tao W Sci Rep; 2018 May; 8(1):7675. PubMed ID: 29769573 [TBL] [Abstract][Full Text] [Related]
33. NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models. Charych DH; Hoch U; Langowski JL; Lee SR; Addepalli MK; Kirk PB; Sheng D; Liu X; Sims PW; VanderVeen LA; Ali CF; Chang TK; Konakova M; Pena RL; Kanhere RS; Kirksey YM; Ji C; Wang Y; Huang J; Sweeney TD; Kantak SS; Doberstein SK Clin Cancer Res; 2016 Feb; 22(3):680-90. PubMed ID: 26832745 [TBL] [Abstract][Full Text] [Related]
34. Increased antitumor effects using IL-2 with anti-TGF-β reveals competition between mouse NK and CD8 T cells. Alvarez M; Bouchlaka MN; Sckisel GD; Sungur CM; Chen M; Murphy WJ J Immunol; 2014 Aug; 193(4):1709-16. PubMed ID: 25000978 [TBL] [Abstract][Full Text] [Related]
35. Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I Wolf NK; Blaj C; Picton LK; Snyder G; Zhang L; Nicolai CJ; Ndubaku CO; McWhirter SM; Garcia KC; Raulet DH Proc Natl Acad Sci U S A; 2022 May; 119(22):e2200568119. PubMed ID: 35588144 [TBL] [Abstract][Full Text] [Related]
36. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors. Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E MAbs; 2021; 13(1):1950264. PubMed ID: 34325617 [TBL] [Abstract][Full Text] [Related]
37. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform. Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K MAbs; 2019; 11(4):666-680. PubMed ID: 31046547 [TBL] [Abstract][Full Text] [Related]
38. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival. Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM Cancer Immunol Immunother; 2013 Aug; 62(8):1303-13. PubMed ID: 23661160 [TBL] [Abstract][Full Text] [Related]
39. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity. Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527 [TBL] [Abstract][Full Text] [Related]
40. MB2033, an anti-PD-L1 × IL-2 variant fusion protein, demonstrates robust anti-tumor efficacy with minimal peripheral toxicity. Park YJ; Kim S; Bang H; Kang SC; Cho S; Park JE; Jung S; Kim HH Cancer Immunol Immunother; 2024 Jun; 73(8):157. PubMed ID: 38834889 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]